Last reviewed · How we verify
Anti tuberculosis chemotherapy
At a glance
| Generic name | Anti tuberculosis chemotherapy |
|---|---|
| Also known as | 2 months Isoniazid, Rifampicin, Ethambutol, Pyrazinamide （2HRZE） |
| Sponsor | Beijing Chest Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Butterfly Pea Flower (Clitoria Ternatea) for Adjuvant TB Treatment (EARLY_PHASE1)
- Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis
- Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis (PHASE4)
- BCG Revaccination in Children and Adolescents (PHASE3)
- Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis (PHASE2, PHASE3)
- Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB (NA)
- Tuberculosis Treatment Shortening Trial (PHASE3)
- Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti tuberculosis chemotherapy CI brief — competitive landscape report
- Anti tuberculosis chemotherapy updates RSS · CI watch RSS
- Beijing Chest Hospital portfolio CI